FGF23, X-Linked Hypophosphatemia (XLH) and Tumor-Induced Osteomalacia (TIO): Emerging Treatments

Released On
October 21, 2020

Expires On
October 21, 2021

Media Type

Completion Time
60 minutes

Endocrinology, Genetics, Hematology-Oncology, Neonatology, Pain Management, Pathology, Pediatrics, Physiatry, Primary Care, Radiology, Surgery

Neonatal, Oncology, Pain, Pediatrics, Radiology, Surgery

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by EXCEL CONTINUING EDUCATION.

This activity is supported in part by an independent education grant from ULTRAGENYX.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Physicians — maximum of 1.0 ABIM MOC points

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This CME activity is designed to meet the educational needs of pediatric and adult endocrinologists, pediatricians, oncologists, and other HCPs who may contribute to the multidisciplinary team, such as radiologists, pathologists, nurse practitioners, and physician assistants interested in increasing their knowledge regarding XLH and TIO, as well as to improve competence in diagnosing and treating these diseases.

Program Overview

This CME-accredited on-demand webinar will highlight therapeutic advances for managing patients with XLH and TIO. Dr. Kathryn Dahir, a key opinion leader in the field of endocrinology, will first cover clinical characteristics, including best practices for management, followed by recent clinical trial data addressing the FGF23 link between both disorders. Devising treatment plans that incorporate the latest developments in the management of these disorders will also be addressed.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Increase knowledge regarding the etiology and pathogenesis of FGF-23 mediated phosphate disorders.
  • Identify clinical manifestations and diagnostic methods to make a timelier diagnosis of XLH and TIO.
  • Assess recent developments in the treatment of these two FGF-23 linked disorders
  • Effectively integrate new evidence-based treatment strategies into clinical practice


Kathryn M. Dahir, MD

Kathryn M. Dahir, MD

Professor of Medicine
Vanderbilt University Medical Center
Program for Metabolic Bone Disorders
Endocrinology and Diabetes
Nashville, TN


Dr. Dahir received her undergraduate education at the University of Virginia and attended medical school at Eastern Virginia Medical School. She completed her internship and residency in internal medicine at Vanderbilt University Medical Center in Nashville, Tennessee. She completed her fellowship in endocrinology and metabolism at Vanderbilt University Medical Center and then joined the faculty. She is a Professor of Medicine in the Division of Endocrinology and Metabolism at the Vanderbilt University Medical Center and is the founder and Course Director for the Endocrinology and Rheumatology Metabolic Bone Fellows conference.

Dr. Dahir's clinical and research interests are calcium- and bone-related disorders including hypophosphatasia, osteogenesis imperfecta, tumor induced osteomalacia, fracture nonunion, hyperparathyroidism, osteoporosis, and rickets. She is the principal investigator for multiple studies for patients with rare skeletal dysplasia including Hypophosphatasia (HPP), Osteogenesis Imperfecta (OI), X-Linked Hypophosphatemic Rickets (XLH) and Fibrous Dysplasia Ossificans Progressiva (FOP). She is an investigator in collaboration with Vanderbilt bioinformatics faculty examining, the significance of adults with both dominant negative mutations for the disorder, hypophosphatasia, and low alkaline phosphatase levels. She has multiple collaborative research endeavors within the Department of Orthopedics, Physical therapy, Audiology and Engineering.

On a national level, Dr. Dahir has served on the Endocrine Society committee as the bone and calcium disorders expert leading the development of the maintenance of certification and ESAP products. She is a board member of the Magic Foundation Scientific Board, the HPP Registry Scientific Advisory Board and has been named a U.S. News and World Report Top Doctor for the past 10 years.

Accreditation Statement

EXCEL Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

EXCEL Continuing Education designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosures of Conflicts of Interest

Kathryn M. Dahir, MD

  • Consultant: Ultragenyx
  • Advisory Board Member: Alexion
  • Research Support Fees: Ultragenyx, Alexion, Mereo, and Regeneron

Eric Imel, MD (peer reviewer), has received research grants and consulting fees as a site investigator and advisory board member for Ultragenyx.

EXCEL Continuing Education staff have no relevant financial information to disclose.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form.
Certificates will be emailed to the participant

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

EXCEL CONTINUING EDUCATION requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.


This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Contact Information

For CME questions please contact: info@excelcme.com